Differential Target Multiplexed™ SCS
endurance therapy Spinal cord stimulation

Differential Target Multiplexed™ SCS endurance therapy is a spinal cord stimulation (SCS) therapy available to treat patients with chronic, intractable pain.

Access clinical posters

DTM™ SCS endurance
therapy overview

Building on the foundation of Differential Target
Multiplexed™ (DTM) spinal cord stimulation (SCS),
DTM™ SCS endurance therapy is an energy modified
multiplexed therapy offering meaningful pain relief,
satisfaction, and quality of life improvements.1 
This enables you to personalize care for those seeking
recharge-free longevity or less frequent recharging.

Inspired by science

DTM™ SCS therapy options are inspired by decades of basic science research and preclinical understanding. In a preclinical study, the DTM™ programming (DTMP) derivatives modulated neuro-inflammatory processes more than low-rate SCS.†2

Clinical results show meaningful pain relief

Study objectives

DTM™ SCS endurance therapy study is a prospective, multicenter, single-arm study designed to evaluate the long-term efficacy and energy use of DTM™ SCS endurance therapy.1

Primary objective: To evaluate the effectiveness of DTM™ SCS endurance therapy in reducing overall pain intensity at 3-months follow up.

Secondary objectives with follow up to 12-months:

  • Characterize changes in pain intensity for overall, back, and leg pain
  • Characterize programming parameters associated with energy use
  • Characterize changes in functional disability as measured by Oswestry disability index (ODI)
  • Characterize subject satisfaction
  • Characterize therapy safety data

12-Month Outcomes

Meaningful
pain relief

4.6

cm reduction in VAS for overall pain
from baseline to 12 months1

Mean overall VAS

Overall pain

Note: *Subjects were excluded from analysis at 6-Months due to programming changes from DTMTM SCS endurance therapy (N=1) and due to study exit (N=1). **Subjects were excluded from analysis at 12-Months due to programming changes from DTMTM SCS endurance therapy (N=2) and due to study exit (N=1)​

Meaningful quality of
life improvements

76%

of patients improved in degree of disability
at 12-month follow up1

Meaning ODI scores

Quality of life graph

Therapy satisfaction

86%

of patients were
satisfied with therapy1

Long lasting

5½-7½

years of recharge-free longevity
estimated using actual
12-month programming data3

Save time

5 minutes

estimated daily rapid recharge
or recharge less frequently
(1 hour every 12 days)3

Superior
pain relief

DTM™ SCS offers proven pain relief backed by data. Available on Inceptiv™ and Intellis™ SCS.

Learn about the therapy

Vanta™ SCS neurostimulator

High performance and recharge free. Experience DTM™ SCS endurance therapy on Vanta™.

Learn more

Inceptiv™ SCS neurostimulator 

Inceptiv™ is the most advanced spinal cord stimulator with closed-loop technology.

Discover Inceptiv™ SCS

† Note: Data obtained from animal studies should not be extrapolated to clinical/human results.

1

Peacock, Provenzano, Fishman, et al. Long-Term Clinical Outcomes of a Low-Energy Derivative Study of Differential Target Multiplexed™ Spinal Cord Stimulation. Poster presented at: North American Neuromodulation Society (NANS) 26th Annual Meeting; Jan 12-15, 2023; Las Vegas, NV.

2

Cedeno D, Vallejo R, Platt D, et al. Differential target multiplexed SCS using reduced energy parameters in an animal model of neuropathic pain. Poster presented at: American Society of Pain and Neuroscience (ASPN) annual meeting. July 22&nash;25, 2021.

3

Provenzano, Amirdelfan, Grewal, et al. Modeling the Impact of a Differential Target Multiplexed Derivative on Rechargeable and Recharge-Free Spinal Cord Stimulation Systems. Poster presented at: American Society of Pain & Neuroscience (ASPN) 5th Annual Conference: July 13-16, 2023; Miami Beach, FL.